Business of Cannabis | Europe

Germany's BMEL has officially approved adult-use cannabis research projects, enabling 27 municipalities, universities, and businesses to begin exploring regulated sales. With studies focused on illicit market reduction, youth protection, and consumer safety, could these pilots be the blueprint for broader legalization across the country? Share your thoughts👇 https://lnkd.in/eH4F9iB2

The UK Food Standards Agency (FSA) held its monthly board meeting to explore the future of CBD regulation in the #UK. Discussions highlighted a potential shift toward a 0% THC policy, with board members emphasizing undetectable #THC levels as the regulatory goal for #CBD products. This approach could significantly impact full-spectrum products and industry practices. The meeting also addressed challenges around the "public list" of temporarily sanctioned products and licensing requirements for CBD businesses, with further clarity expected in the coming months. Read here: https://lnkd.in/dqTmp-sQ Mentions: Robert Jappie, Fieldfisher, Rebecca Sudworth, Fiona Gately, British Retail Consortium (BRC).

Astrasana Holding AG Japan has joined forces with GSI Creos Corporation to enhance the supply of premium Swiss-made CBD raw materials across Japan. This partnership leverages AstraSana’s expertise and GSI Creos’ extensive networks to establish a reliable supply chain, ensuring customers receive safe, high-quality products. Together, the companies are driving innovation and supporting the growth of Japan’s CBD market. Learn more: https://lnkd.in/dRTYGX6t

BRITISH CANNABIS™ has officially entered the medical cannabis space with its BRITISH CANNABIS™ Medicines (BCM) range, offering strain-specific sublingual oils designed for consistent dosing and maximum efficacy. Chief Revenue Officer Adam W. shared how the team’s mission to create safer, more effective alternatives has led to the development of eight unique strains. These oils cater to patients' individual needs while maintaining full-plant extracts for enhanced bioavailability and the entourage effect. By combining innovative product design with a commitment to quality and UK-based production, BCM aims to shift the market focus from flower to oils, providing a trusted option for cannabis-naive and experienced patients alike. Explore how BCM is transforming the UK cannabis industry here: https://lnkd.in/gPsHeZEz #MedicalCannabis #CannabisInnovation #UKCannabis #CannabisOils

Paralab Green, led by CEO Rui Soares, is driving advancements in cannabis production with cutting-edge technology. In our conversation, Rui shared insights on overcoming GMP compliance challenges, the shift toward non-irradiation decontamination methods, and how automation is transforming efficiency and consistency for producers. With over 30 years of experience in regulated industries, Paralab is setting new standards for EU-GMP compliance and supporting producers worldwide. Learn how Paralab Green is shaping the future of cannabis innovation here: https://lnkd.in/ezzvubXj #CannabisTech #Innovation #GMP #Automation

European news round-up 🗞️ 📊 Poland enacts new restrictions on online medical cannabis prescriptions 🇮🇪 Ireland's election: Cannabis reform on the table but coalition challenges remain 🇲🇹 Concerns rise over potential shift in Malta’s cannabis policy https://lnkd.in/eQ6YF3UC

Starting April 2025, 5,000 general practitioners in Czechia will be permitted to prescribe medical cannabis for chronic pain, significantly broadening access to legal treatments. Previously, only 200 specialists were authorized to prescribe, leaving many patients underserved. Read here: https://lnkd.in/ehssjb6X While advocates welcome this progress, challenges remain. GPs are restricted to chronic pain prescriptions, and further reforms are needed to include treatments for children with conditions like cancer and epilepsy. How might this change reshape access to medical cannabis in Czechia?

Last week, the Business of Cannabis: Berlin Executive Summit brought together over 150 leaders to assess Germany’s cannabis market under the CanG and explore its uncertain future amid political upheaval. Panels addressed key topics, including the potential impact of the 2025 elections on cannabis policies, challenges in #CBD and #hemp regulation, and the growing role of cannabis clubs as an alternative to delayed reforms. Medical cannabis remains #Germany's dominant market segment, with simplified imports and prescriptions driving growth, while long-term success hinges on innovation, strategic alliances, and lean operations to navigate regulatory uncertainty and market competition. Read the full write up, here: https://lnkd.in/ehc7_8Zc • Stephen Murphy • Georg Wurth • Farida Hussain • Duc Anh Dang • Pablo Zuanic • Sasho Stefanoski,PhD • Finn Age Hänsel • Yuval Soiref • Larissa Mößmer • Lisa Haag • Timo Bongartz • Vladimir Kofcegarski • Olivia Ewenike • Niels Lutzhöft • Marijn Roersch van der Hoogte • Frederike S. Fäscher • Philipp Ferrer • Dr. Constantin von der Groeben • Benedikt Sons • Dr. Peter Reinhardt • Bundesinstitut für Arzneimittel und Medizinprodukte) • Sanity Group • Cannovum Cannabis AG • Cannamedical Pharma • OSRAM • Prohibition Partners

European Stocks Review 📊 📉 Argent BioPharma to delist from London Stock Exchange 🩺 Mixed picture for Danish cannabis stocks amid medical scheme changes 🧪 Ananda Developments Plc advances MRX1 for clinical trials https://lnkd.in/ebzzbg2J

Our very own Rupa Shah and Graham Woodward had an insightful conversation with Business of Cannabis | Europe last week to talk about best practices for #compliance in the UK's #medicalcannabis sector. Our exceptional leadership team, including Rupa and Graham, have a stellar track record of leading rapid growth in complex, highly-regulated sectors. Meaning Releaf is able to expertly handle a difficult challenge: going to market in a fully compliant manner; a task that is not easy in this industry. 'Compliance is integrated into every part of our culture. [...] Everyone - whether in marketing, patient support, or any other team - understands that compliance is critical for gaining the trust of our patients.' This ethos is what drives our success and is what sets us part to lead the UK's #medicalcannabis sector. By embedding compliance into every aspect of our operations, both internal and external, we ensure that we are delivering the highest standards of care and trust to our patients. Thank you Business of Cannabis | Europe for hosting this discussion; it's through conversations like these that Releaf continues to raise the bar for #compliance and patient-focused innovation in the industry.